A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

ClinicalTrials.gov ID: NCT05473910

Public ClinicalTrials.gov record NCT05473910. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/3 Study Evaluating the Efficacy and Safety of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor, MMUD, or MUD

Study identification

NCT ID: NCT05473910
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: TScan Therapeutics, Inc.; Industry
Enrollment: 310 participants

Conditions and interventions

Conditions

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 31, 2022
Primary completion: May 31, 2026
Completion: May 31, 2028
Last update posted: Jul 20, 2026

2022 – 2028

United States locations

U.S. sites: 21
U.S. states: 15
U.S. cities: 19

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	Recruiting
University of Colorado - Anschutz Cancer Center	Aurora	Colorado	80045	Recruiting
SCRI - Colorado Blood Cancer Institute	Denver	Colorado	80218	Recruiting
Yale	New Haven	Connecticut	06510	Recruiting
Memorial Cancer Institute	Hollywood	Florida	33021	Recruiting
Moffitt Cancer Institute	Tampa	Florida	33612	Recruiting
Northside Hospital	Atlanta	Georgia	30342	Recruiting
Johns Hopkins University	Baltimore	Maryland	21287	Recruiting
Mass General Hospital	Boston	Massachusetts	02114	Recruiting
Dana-Farber Cancer Institute - Hematology/Oncology	Boston	Massachusetts	02215	Recruiting
Karmanos Cancer Institute	Detroit	Michigan	48201	Recruiting
Hackensack University Medical Center	Hackensack	New Jersey	07601	Recruiting
Columbia University	New York	New York	10027	Recruiting
Mount Sinai	New York	New York	10029-6696	Recruiting
University North Carolina	Chapel Hill	North Carolina	27599	Recruiting
University of Pennsylvania	Philadelphia	Pennsylvania	19104	Recruiting
SCRI - TriStar Bone Marrow Transplant	Nashville	Tennessee	37203	Recruiting
St. David's South Austin Medical Center	Austin	Texas	76704	Recruiting
Baylor University Medical Center	Dallas	Texas	75246	Recruiting
MD Anderson	Houston	Texas	77030	Recruiting
Froedert and Medical College of Wisconsin	Milwaukee	Wisconsin	53226	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05473910, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 20, 2026 · Synced Sep 4, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05473910 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →